Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias

Status unconfirmed · Phase 2

Conditions studied: Supra-ventricular Tachyarrhythmias

In brief

The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, RFA versus RFA plus botulinum toxin injection, in patients with supra-ventricular tachyarrhythmias. Results were assessed with the use of an implanted monitoring device (IMD).

Key facts

Study ID

NCT02008461

Run by

Meshalkin Research Institute of Pathology of Circulation

People needed

60

Starts

2013-06-01

Expected to finish

2016-02-01

Last updated by the study team

2015-09-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• atrial flutter, AV nodal re-entry tachycardia, focal atrial tachycardia, WPW syndrome
• secondary atrial fibrillation

You may not qualify if…

• congestive heart failure
• LV ejection fraction < 35%
• left atrial diameter > 60 mm

Where it is running

• State Research Institute of Circulation Pathology — Novosibirsk, Russia (enrolling)
• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.